CervoMed已正式确定其针对路易体痴呆症患者的三期临床试验的最终配方及给药方案。这一关键决策标志着该公司在推进神经退行性疾病治疗研究方面迈出了重要一步,为后续临床试验的开展奠定了坚实基础。
CervoMed已正式确定其针对路易体痴呆症患者的三期临床试验的最终配方及给药方案。这一关键决策标志着该公司在推进神经退行性疾病治疗研究方面迈出了重要一步,为后续临床试验的开展奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.